Pharmaceutical Dissolution Testing Products and Services

Dissolution testing allows for the examination and prediction of the in-vitro behavior of pharmaceutical formulations. Drug release behavior of pre-formulations is made possible by the use of specialized dissolution equipment. By dissolution testing, a researcher can simulate the behavior of capsule, bead, and enteric-coated tablets in-vitro.

Important Applications of Dissolution Testing

  • Quality Control
  • Replicating certain mechanisms of in-vitro drug release
  • Determining if drug behavior meets regulatory standards
  • Dissolution simulation when choosing pharmaceutical excipients

Examples of Pharmaceutical Dissolution Equipment

Paddle apparatus dissolution testing is used to simulate tablet behavior in the gastrointestinal tract. The release behavior of implants and transdermal medications can also be tested with dissolution equipment. The reciprocating cylinder dissolution apparatus ("Bio-Dis") is excellent for examining the dissolution behavior of extended release products. Dissolution analysis is key in determining the homogeneity of the final pharmaceutical product. Whether controlled by the bench user or fully automated, the implementation of a dissolution testing protocol is crucial in the final stages of drug development to ensure the efficacy, safety, and marketability of the final compound.
  • CPHI Frankfurt: Nutraceuticals with a pharmaceutical address

    Friday, October 23, 2026
    A new zone at CPHI Frankfurt 2027 for pharma-grade supplement makers, contract manufacturers and formulators selling into pharmacy and clinical channels - not retail. read more
  • LGM Pharma Acquires Sannova Analytical to Expand Testing Services

    Thursday, October 22, 2026
    LGM Pharma has acquired Sannova Analytical, a contract research laboratory in Somerset, New Jersey, adding bioanalytical services and specialized impurity testing to its pharmaceutical testing business. read more
  • Medpace Revenue Rises 8.5%; Board Approves $1 Billion Buyback

    Thursday, October 22, 2026
    Medpace reported third-quarter revenue of $716 million, up 8.5% from a year earlier, while net income increased to $137.5 million from $111.1 million. Diluted earnings per share rose to $4.84 from $3.86. read more
  • Pharmapack Asia 2026

    Wednesday, October 21, 2026
    The inaugural edition of Pharmapack Asia will be launched in Singapore, building on the established success of the Pharmapack series in Europe. read more
  • IFPAC 2027

    Wednesday, October 21, 2026
    IFPAC® brings together experienced professionals and the next generation of leaders to share in insightful discussions, share applications & solutions, and hear the latest ideas in advanced manufacturing science. read more
We're sorry, no matching articles were found. Please select different filter options and try your search again.
We're sorry, no matching articles were found. Please select different filter options and try your search again.